Tumor immunology top 10 list.
Finn
Olivera J
OJ
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15262, USA.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D019496:Cancer Vaccines / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007157:Immunologic Surveillance / Q000276:immunology; D007167:Immunotherapy / Q000639:trends*; D015166:Monitoring, Immunologic; D009361:Neoplasm Invasiveness / Q000276:immunology / Q000517:prevention & control; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human